New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 11, 2014
09:06 EDTACHN, KMP, DF, PIP, TSLA, EPB, KMI, PCLN, MNKD, TWOU, KMR, SNY, SIGA, PEPOn The Fly: Pre-market Movers
HIGHER: PharmAthene (PIP), up 55% after announcing that a Delaware court awarded the company lump sum expectation damages for the value of its lost profits for SIGA Technologies' (SIGA) smallpox antiviral, Tecovirimat... MannKind (MNKD), up 19% after entering exclusive licensing agreement for development and commercialization of Afrezza inhaled insulin with Sanofi (SNY)... Kinder Morgan (KMI), up 19% after announcing it will acquire all of the outstanding equity securities of Kinder Morgan Energy Partners (KMP), Kinder Morgan Management (KMR) and El Paso Pipeline Partners (EPB)... Tesla (TSLA), up 2.7% following upgrade at Deutsche Bank... Achillion (ACHN), up 6% following upgrades at Wells Fargo and at Piper Jaffray... PepsiCo (PEP), up 0.9% following upgrade at UBS. LOWER: Dean Foods (DF), down 8.6% after reporting Q2 losses that were steeper than expected, saying balance of year "appears rocky," which makes it difficult to provide guidance beyond the immediate quarter... Priceline (PCLN), down 0.7% after reporting Q2 revenue that missed expectations, guiding Q3 EPS below consensus... SIGA Technologies, down 31% after ruling in suit with PharmAthene... 2U (TWOU), down 4.3% after downgraded at Goldman.
News For TSLA;PEP;MNKD;PIP;SIGA;PCLN;DF;SNY;KMI;KMP;KMR;EPB;ACHN;TWOU From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
March 16, 2015
10:41 EDTTSLATesla certified pre-owned program launches, Clean Technica says
Subscribe for More Information
10:28 EDTPEPOptions with increasing implied volatility
Options with increasing implied volatility: PVA NFLX BMRN DNOW MYL TEVA PEP GE
09:37 EDTTSLAActive equity options trading on open
Subscribe for More Information
09:22 EDTTSLAOn The Fly: Pre-market Movers
Subscribe for More Information
08:23 EDTSNYPCSK9 data continues to impress, says Leerink
Subscribe for More Information
07:16 EDTSNYRegeneron Sanofi dupilumab drug can generate $6B+ in revenue, says Bernstein
Bernstein believes that dupilumab, a drug made by Regeneron and Sanofi, has shown strong efficacy in patients with severe atopic dermatitis. The firm notes that the drug is currently in pivotal trials involving patients with severe levels of other common diseases. The firm thinks the drug can generate $1.5B of revenue by 2018 and $3.8B by 2020. Bernstein keeps a $500 price target and Outperform rating on Regeneron.
06:40 EDTSNYPCSK9 studies show potential improvement in heart health, WSJ says
Subscribe for More Information
06:05 EDTTSLATesla volatility low into press conference on update 'to end range anxiety'
Tesla Motors March call option implied volatility is at 39, April is at 37, June is at 40; compared to its 26-week average of 45 according to Track Data, suggesting decreasing price movement into a press conference on Thursday on update 'to end range anxiety,' Musk says.
March 15, 2015
17:57 EDTPEPPepsiCo to invest $500M in Egypt in 2015, Reuters says
PepsiCo's business unit manager for North East Africa Ahmed El Sheikh told Reuters at an investment conference in Sharm El-Sheikhwill that the company will invest $500M in Egypt this year to expand production. Reference Link
17:40 EDTTSLAChina's BYD steps up battery factory race with Tesla, Reuters says
Subscribe for More Information
15:43 EDTTSLATesla press conference on Thursday on update 'to end range anxiety,' Musk says
Tesla CEO Elon Musk tweeted, "Tesla press conf at 9am on Thurs. About to end range anxiety ... via OTA software update. Affects entire Model S fleet." Reference Link
13:04 EDTSNYSanofi, Regeneron announce publication of results of ODYSSEY long term trial
Sanofi (SNY) and Regeneron Pharmaceuticals (REGN) today announced that 18-month results of a Phase 3 trial of Praluent, alirocumab, an investigational therapy, involving 2,341 high risk patients with hypercholesterolemia were published online in The New England Journal of Medicine. In the ODYSSEY LONG TERM trial, Praluent 150 mg every two weeks reduced low-density lipoprotein cholesterol by an additional 62% at week 24 when compared to placebo, the primary efficacy endpoint of the study, with consistent LDL-C lowering maintained over 78 weeks."These results demonstrated the durable efficacy for Praluent when added to maximally-tolerated statin therapy and further reinforce its generally consistent safety profile," said Jennifer Robinson, M.D., M.P.H., Director of the Prevention Intervention Center, Professor, Departments of Epidemiology & Medicine, College of Public Health at the University of Iowa. "Additionally, the post hoc analysis of major cardiovascular events represents an important finding for Praluent -- we look forward to results from the ongoing ODYSSEY OUTCOMES trial, which is prospectively evaluating the potential of Praluent to reduce cardiovascular events."
March 13, 2015
17:33 EDTKMIS&P announces changes to S&P 100 Index
Subscribe for More Information
16:01 EDTTSLAOptions Update; March 13, 2015
Subscribe for More Information
11:23 EDTTSLATesla falls, levels to watch
Subscribe for More Information
11:17 EDTTSLAStocks with call strike movement; TSLA FB
Subscribe for More Information
10:37 EDTSNYSanofi says NHS England de-lists cabazitaxel, aflibercept
Sanofi announcd that NHS England has confirmed that it is de-listing both cabazitaxel and aflibercept from the Cancer Drugs Fund, so that neither of these medicines will be available to new patients in England on the NHS. It added, "However regarding cabazitaxel NHS England have agreed to engage in talks to explore immediate ways of maintaining access to patients until it is reviewed by NICE." Tarja Stenvall, General Manager for Sanofi in the UK, commented, "We are hugely disappointed that cabazitaxel and aflibercept have been cut from the CDF and that new patients in England will no longer have access to these crucial cancer treatments. However NHS England remains in dialogue with Sanofi to explore immediate ways of maintaining access to patients for cabazitaxel until the outcome of any NICE review. Our concern is for patients who should continue to have access to cabazitaxel until a longer term solution is reached and who may feel confused and uncertain until this happens."
09:50 EDTTSLAActive equity options trading on open
Subscribe for More Information
08:56 EDTTSLATesla seeking sales executives as sales VP Guillen changes roles, Bloomberg says
Subscribe for More Information
07:33 EDTTSLATesla 2015 earnings estimate slashed 80% at Deutsche Bank
Deutsche Bank cut its 2015 earnings estimate for Tesla by 80% to 11c from 52c to account for the car maker's exposure to the weakening euro. Deutsche points out 30% of Tesla's global sales are exposed to the euro. The firm also reduced its 2016 earnings estimate to $1.75 from $2.00 while noting its out year assumptions remain intact. Deutsche's new estimates are well below the current consensus expectations of 79c and $4.20 for Tesla’s 2015 and 2016, respectively. The firm keeps a Buy rating and $245 price target on Tesla, however, believing the company’s cost structure and car sale prices will "overwhelm" adverse currency moves over the longer term. Shares of the electric car maker closed yesterday down $2.67 to $191.07.
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use